If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
== Georgian military interviews == According to Georgian military interviewed by EurasiaNet, they believed their action initially intended to restore security for Georgian villages in South Ossetia, with one lieutenant from 4th Brigade saying: "Our goal was to put an end to fighting in the area and take control. Nobody in the army expected a war with Russia." Georgian soldiers said they had earlier anticipated an attack from Abkhazia, with the 4th Brigade lieutenant saying that they "were preparing for something in May when Georgia was denied NATO membership [a Membership Action Plan]." There "were no preparations made" for a military action in South Ossetia in August, since "Many were on vacation and we were preparing to go Iraq in the fall." The 4th brigade loaded tanks and missile launchers on a train, destined for the city of Gori, after receiving an unexpected alarm call on 7 August 2008. The 4th Brigade began an operation against South Ossetian separatists during the night of 7–8 August, which marked their first combat, and undertook action in three directions, one of which was intended to deflect South Ossetians from the main Georgian goal. One anonymous mid-ranking commander said Georgian army attempted to take control over an important road to the north of Tskhinvali (leading to the Roki Tunnel), which was being defended by South Ossetian garrison near the village of Tbeti and the first Russian tanks arrived during this battle. The anonymous Georgian commander also said, "We destroyed one tank after another, but they kept coming."
==== Accidental myiasis ==== Accidental myiasis, also called pseudomyiasis, occurs when fly larvae are ingested or deposited on the body, leading to an infestation. It is caused by flies that have no preference or need to develop in a host but may do so on rare occasions. Transmission occurs through accidental deposit of eggs on oral or genitourinary openings, or by swallowing eggs or larvae that are on food. Enteric pseudomyiasis can cause nausea, vomiting and gastrointestinal upset. The cheese fly (Piophila casei) sometimes causes myiasis through intentional consumption of its maggots (which are contained in the traditional Sardinian delicacy casu marzu). Other flies that can accidentally cause myiasis are:
==== Fabric properties ==== Should not cause damage through friction with the original fabric Be of similar or lighter weight than the original fabric. Match the original fabric with consideration of the loss of color or sheen Be of a tight enough weave to exclude dust if being used as a barrier
Eosin is most often used as a counterstain to hematoxylin in H&E (haematoxylin and eosin) staining. H&E staining is one of the most commonly used techniques in histology. Tissue stained with haematoxylin and eosin shows cytoplasm stained pink-orange and nuclei stained darkly, either blue or purple. Eosin also stains red blood cells intensely red. For staining, eosin Y is typically used in concentrations of 1 to 5 percent weight by volume, dissolved in water or ethanol. For prevention of mold growth in aqueous solutions, thymol is sometimes added. A small concentration (0.5 percent) of acetic acid usually gives a deeper red stain to the tissue. It is listed as an IARC class 3 carcinogen (safe).
Sources: en.wikipedia.org
2C-B has been reported to be an allosteric or non-competitive serotonin transporter (SERT) inhibitor or serotonin reuptake inhibitor, albeit of very low potency. Although 2C-B itself was not evaluated, other closely related members of the 2C series, including 2C-C, 2C-D, 2C-E, 2C-I, and 2C-T-2, all showed no activity as monoamine releasing agents of serotonin, norepinephrine, or dopamine (EC50 = >100,000 nM or "inactive"). 2C-B shows dopaminergic actions mediated by the dopamine transporter (DAT) in monkeys but not in rodents. 2C-B produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It shows reinforcing effects in monkeys but not in rodents. The drug also shows potent and efficacious anti-inflammatory effects in preclinical research. In contrast to MDMA, which robustly increases oxytocin levels and produces associated entactogenic effects, 2C-B minimally affects oxytocin levels in humans.
== Appearances == The Headcrab debuted in Half-Life (1998) as an enemy that attacks protagonist Gordon Freeman and other surviving humans by leaping at them and biting them. Headcrabs first appear when a portal is opened, sending various interdimensional beings into the game's world and sending the Black Mesa lab into chaos. Throughout the game, the player encounters bodies with Headcrabs on their head, some of which becoming animated and attacking living people. In the sequel, Half-Life 2, the Headcrab and Headcrab Zombies return in a similar capacity. Headcrabs can be found in various environments, and the main antagonists, the Combine, who have taken control of the world post-invasion, have been attacking civilian and resistance groups by shooting rockets with Headcrabs in them to infect the population. Other Headcrabs appear, including a fast one and a poison one, the latter of which can put Gordon in serious danger if bitten. The character Isaac Kleiner manages to debeak a Headcrab, keeping it as a pet called Lamarr. Headcrabs also appear in Half-Life: Alyx, a virtual reality game. Fast-moving Headcrabs and Zombies were originally considered for inclusion, but were removed due to tests finding that they moved too fast for players to properly react. Outside of the Half-Life series, the Headcrab makes multiple cameo appearances. Multiple games, such as Vindictus and the Steam releases of Phantasy Star Online 2, Death Stranding, and Fall Guys featured accessories based on the Headcrab.
Amphetamine is a potent psychostimulant of the phenethylamine class that is approved for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Amphetamine is also used off-label as a performance and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. Although it is a prescription medication in many countries, unauthorized possession and distribution of amphetamine is often tightly controlled due to the significant health risks associated with uncontrolled or heavy use. As a consequence, amphetamine is illegally manufactured in clandestine labs to be trafficked and sold to users. Based upon drug and drug precursor seizures worldwide, illicit amphetamine production and trafficking is much less prevalent than that of methamphetamine. The first pharmaceutical amphetamine was Benzedrine, a brand of inhalers used to treat a variety of conditions. Because the dextrorotary isomer has greater stimulant properties, Benzedrine was gradually discontinued in favor of formulations containing all or mostly dextroamphetamine. Presently, it is typically prescribed as mixed amphetamine salts, dextroamphetamine, and lisdexamfetamine. Amphetamine is a norepinephrine–dopamine releasing agent (NDRA). It enters neurons through dopamine and norepinephrine transporters and facilitates neurotransmitter efflux by activating TAAR1 and inhibiting VMAT2. At therapeutic doses, this causes emotional and cognitive effects such as euphoria, change in libido, increased arousal, and improved cognitive control.
Sources: en.wikipedia.org
Anne Hardy argues that widespread public education of food hygiene can be useful, particularly through media (TV cookery programmes) and advertisement. She points to the examples set by Scandinavian societies.
Malagasy protesters in September–October 2025 used the symbol as a gesture against the government for inadequate water and power, with protesters using a variant of the flag with a pink-and-green satroka hat, traditional of the Betsileo people, in place of the regular straw hat. The icon was adopted by social media accounts associated with protesters. By 11 October, the military CAPSAT unit had refused to fire on the protesters and they launched a coup the following day, resulting in the flight and later impeachment of President Andry Rajoelina. Protesters proceeded to hang the flag at the capital Antananarivo's Place du 13 Mai. Some protest leaders, opposed to the military takeover, began distributing T-shirts with the Malagasy variant of the flag to protesters after the coup.
Atherosclerosis, formerly considered a lipid storage disorder, is now understood as a chronic inflammatory condition involving the arterial walls. Research has established a fundamental role for inflammation in mediating all stages of atherosclerosis from initiation through progression and, ultimately, the thrombotic complications from it. These new findings reveal links between traditional risk factors like cholesterol levels and the underlying mechanisms of atherogenesis. Clinical studies have shown that this emerging biology of inflammation in atherosclerosis applies directly to people. For instance, elevation in markers of inflammation predicts outcomes of people with acute coronary syndromes, independently of myocardial damage. In addition, low-grade chronic inflammation, as indicated by levels of the inflammatory marker C-reactive protein, prospectively defines risk of atherosclerotic complications, thus adding to prognostic information provided by traditional risk factors, such as LDL levels. Moreover, certain treatments that reduce coronary risk also limit inflammation. Notably, lipid-lowering medications such as statins have shown anti-inflammatory effects, which may contribute to their efficacy beyond just lowering LDL levels. This emerging understanding of inflammation's role in atherosclerosis has had significant clinical implications, influencing both risk stratification and therapeutic strategies.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.